ENRUHE
PF-Atlas › Clinical Trials › NCT02141087

Expanded Access Program : Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Pirfenidone · Not specified

Registry ID
NCT02141087
Phase
Not specified
Status
Approved For Marketing
Drug / intervention
Pirfenidone
Sponsor
Genentech, Inc.

About this trial

Pirfenidone is evaluated in NCT02141087, a idiopathic pulmonary fibrosis study sponsored by Genentech, Inc.. Current status: Approved For Marketing.

View NCT02141087 on ClinicalTrials.gov →

Explore related

All Pirfenidone trialsAll IPF trials

Related trials

Pirfenidone — NCT00001959pirfenidone — NCT00662038Pirfenidone — NCT02951429Pirfenidone — NCT00287729Pirfenidone — NCT01504334Pirfenidone — NCT02932566
Medical disclaimer. This page summarizes public trial data for NCT02141087 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.